Lung research needs support as fifth of UK diagnosed with respiratory condition.
Earlier use of montelukast could save NHS millions, says NICE.
MSD drug will not face competition from BMS rival in this use.
But drug will not be funded for longer than two years.
Companies confirm takeover talks.
Firms extend existing respiratory deal.
Compelling data from FULFIL study puts GSK in pole position
But UK registry data falls short.